• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by ProKidney Corp.

    3/18/26 4:07:55 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PROK alert in real time by email
    S-8 1 prok-20260318.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 18, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ProKidney Corp.

    (Exact name of registrant as specified in its charter)

    Delaware

    98-1586514

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification Number)

    2000 Frontis Plaza Blvd., Ste 250

    Winston-Salem, NC 27103

    (Address, including zip code, of Principal Executive Offices)

    ProKidney Corp. 2022 Incentive Equity Plan

    (Full Title of the Plan)

    Bruce Culleton, M.D.

    Chief Executive Officer

    ProKidney Corp.

    2000 Frontis Plaza Blvd., Ste 250

    Winston-Salem, NC 27103

    Telephone: (336) 999-7028

    (Name, address and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    

    Accelerated filer

    

    Non-accelerated filer

    

    Smaller reporting company

    

    Emerging growth company

    

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 


    EXPLANATORY NOTE

    This Registration Statement registers 15,053,502 additional Class A common stock, par value $0.0001 per share (“Class A Common Stock”), of ProKidney Corp. (the “Registrant”) under the Registrant’s 2022 Incentive Equity Plan (the “2022 Plan”), representing an increase of 15,053,502 shares of Class A common stock reserved for issuance under the 2022 Plan, effective January 1, 2026 by operation of the “evergreen” provision contained in the 2022 Plan. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to one or more employee benefit plans is effective (File Nos. 333-267414, 333-270920, 333-278176 and 333-285975). The information contained in the Registrant’s registration statements on Form S-8 (File Nos. 333-267414, 333-270920, 333-278176 and 333-285975), to the extent not otherwise amended or superseded by the contents hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission are incorporated herein by reference:

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on March 18, 2026;

    (b) The Registrant’s Current Report on Form 8-K, as filed with the Commission on February 2, 2026; and

    (c)the description of the Company’s common stock, included in the final prospectus dated April 28, 2025 (filed pursuant to Rule 424(b)(3)) to its Registration Statement on Form S-4 dated March 31, 2025 (File No. 333-286278)) under the caption “Description of Securities” therein, including any amendment or report filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 8.

    Exhibits.

    Exhibit
    Number

    Exhibit Description

    Filed
    Herewith

    Incorporated by
    Reference herein from
    Form or Schedule

    Filing Date

    SEC File/
    Reg.
    Number

    4.1

    Certificate of Incorporation of ProKidney

    Form 8-K12B
    (Exhibit 3.1)

    7/3/2025

    001-40560

     

    4.2

     

    By-laws of ProKidney Corp.

     

     

     

    Form 8-K12B
    (Exhibit 3.2)

     

    7/3/2025

     

    001-40560

     

     

     

     

     

     

     

     

     

     

     


    4.3

     

    Certificate of Corporate Domestication of ProKidney Corp.

     

     

     

    Form 8-K12B

    (Exhibit 3.3)

     

    7/3/2025

     

    001-40560

     

     

     

     

     

     

     

     

     

     

     

    4.4

     

    Stock Certificate for Class A Common Stock ProKidney

     

     

     

    Form 8-K12B
    (Exhibit 4.1)

     

    7/3/2025

     

    001-40560

     

     

     

     

     

     

     

     

     

     

     

    4.5

     

    Stock Certificate for Class B Common Stock ProKidney

     

     

     

    Form 8-K12B
    (Exhibit 4.2)

     

    7/3/2025

     

    001-40560

     

     

     

     

     

     

     

     

     

     

     

    5.1

    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

    X

    23.1

    Consent of Ernst & Young LLP, independent registered public accounting firm

    X

    23.2

    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)

    X

    24.1

    Power of Attorney (included on the signature page hereof)

    X

    99.1+

    ProKidney Corp. 2022 Incentive Equity Plan

    Form 8-K
    (Exhibit 10.11)

    7/15/2022

    001-40560

     

     

     

     

     

     

     

     

     

     

     

    99.2+

     

    First Amendment to the ProKidney Corp. 2022 Incentive Equity Plan

     

     

     

    Form 8-K12B (Exhibit 10.5)

     

    7/3/2025

     

    001-40560

    107

    Calculation of registration fee

    X

    + Management contract or compensatory plan or arrangement.


    Signatures

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Winston-Salem, State of North Carolina, on March 18, 2026.

    PROKIDNEY CORP.

    By:

    /s/ Bruce Culleton, M.D.

    Bruce Culleton, M.D.

    Chief Executive Officer

     


    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints each of Bruce Culleton, M.D. and James Coulston, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dated indicated.

    Signature

    Title

    Date

     

     

     

     

     

    /s/Bruce Culleton, M.D.

    Chief Executive Officer and Director
    (Principal Executive Officer)

    March 18, 2026

    Bruce Culleton, M.D.

    /s/James Coulston, CPA

    Chief Financial Officer (Principal Financial and Accounting Officer)

    March 18, 2026

    James Coulston, CPA

    /s/Pablo Legorreta

    Chairman

    March 18, 2026

    Pablo Legorreta

    /s/William F. Doyle

    Director

    March 18, 2026

    William F. Doyle

    /s/Jennifer Fox

    Director

    March 18, 2026

    Jennifer Fox

    /s/José Ignacio Jimenez Santos

    Director

    March 18, 2026

    José Ignacio Jimenez Santos

    /s/Alan M. Lotvin, M.D.

    Director

    March 18, 2026

    Alan M. Lotvin, M.D.

    /s/Brian J.G. Pereira, M.D.

    Director

    March 18, 2026

    Brian J.G. Pereira, M.D.

     

     

    /s/Uma Sinha, Ph.D.

    Director

    March 18, 2026

    Uma Sinha, Ph.D.

     


    Get the next $PROK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PROK

    DatePrice TargetRatingAnalyst
    12/16/2025$12.00Buy
    H.C. Wainwright
    6/30/2025$1.00Neutral → Underperform
    BofA Securities
    9/30/2024Neutral
    JP Morgan
    9/10/2024$6.00Buy
    Guggenheim
    3/7/2024$3.00Equal-Weight
    Morgan Stanley
    1/2/2024Buy → Neutral
    BofA Securities
    7/25/2023$16.00Buy
    BTIG Research
    12/21/2022$15.00Buy
    Jefferies
    More analyst ratings

    $PROK
    SEC Filings

    View All

    SEC Form S-8 filed by ProKidney Corp.

    S-8 - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:07:55 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:03:55 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by ProKidney Corp.

    10-K - PROKIDNEY CORP. (0001850270) (Filer)

    3/18/26 4:01:34 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PROK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    4/24/25 4:15:43 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Control Empresarial De Capitales S.A. De C.V. bought $18,690 worth of Class A Ordinary Shares (25,000 units at $0.75) (SEC Form 4)

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    4/21/25 4:37:34 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Control Empresarial De Capitales S.A. De C.V. bought $74,820 worth of Class A Ordinary Shares (100,000 units at $0.75) (SEC Form 4)

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    4/18/25 4:15:51 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PROK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProKidney Reports Full Year 2025 Financial Results and Business Highlights

    On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("Pro

    3/18/26 4:00:00 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

    WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 44th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 14, 2026Time: 8:15am PSTFormat: PresentationWebcast: Link The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website at www.prokidney.c

    1/6/26 7:30:00 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PROK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Coulston James

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    3/3/26 7:59:02 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Regulatory Officer Weber Darin J.

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    3/3/26 7:58:38 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Legal Officer Girolamo Todd C

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    3/3/26 7:58:18 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PROK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ProKidney Corp. with a new price target

    H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

    12/16/25 9:01:44 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Corp. downgraded by BofA Securities with a new price target

    BofA Securities downgraded ProKidney Corp. from Neutral to Underperform and set a new price target of $1.00

    6/30/25 7:57:01 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    JP Morgan initiated coverage on ProKidney Corp.

    JP Morgan initiated coverage of ProKidney Corp. with a rating of Neutral

    9/30/24 7:50:41 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PROK
    Leadership Updates

    Live Leadership Updates

    View All

    ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

    Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentiall

    9/3/24 7:30:00 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Reports Business Updates and First Quarter 2024 Financial Results

    Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024Strengthened leadership team with appointment of two key hires across Clinical and Technical OperationsEnded the first quarter with $329 million in cash and cash equivalents and marketable securities, su

    5/10/24 7:00:00 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

    WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential to preserve kidney function in patients with type 2 diabetes mellitus and advanced kidney disease, we look forward to the REGEN-007 Phase 2 interim data readout mid-year," said Bruce Culleton, Ch

    3/21/24 7:49:56 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PROK
    Financials

    Live finance-specific insights

    View All

    ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

    Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both PROACT 1 and PROACT 2 Phase 3 trialsManagement to host live webcast today at 8:00 a.m. ET WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical

    6/10/24 6:30:00 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Reports Third Quarter Financial Results

    WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. "Building off of our positive corporate update, and with nearly $400 million in cash, cash equivalents and marketable securities as of September 30th of this year, ProKidney continues to be well capitalized to continue executing on both of our Phase 2 and Phase 3 trials in high-risk CKD patients in need," said James Coulston, Chief Financial Officer at ProKidney. "With cash expected to fund operations into the

    11/14/23 6:05:00 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

    Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage 3b and 4 diabetic CKD at highest risk of advancing to kidney failure and need for renal replacement therapy Dr. Bruce Culleton appointed ProKidney CEO following Dr. Tim Bertram's transition to advisory role Sufficient capital to fund operations into fourth quarter 2025 ProKidney to host conference call and webcast tomorrow at 8:00 a.m. ET WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellu

    11/13/23 5:02:13 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PROK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

    SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

    11/8/24 10:13:46 AM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

    SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

    10/22/24 3:32:15 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by ProKidney Corp.

    SC 13D/A - PROKIDNEY CORP. (0001850270) (Subject)

    6/25/24 4:08:10 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care